[At the crossroads between B lymphoproliferative syndromes to autoimmune diseases are CD5-positive B-lymphocytes: a new hypothesis].
Cells of most of the chronic lymphoid leukemias of the B cell lineage express the CD5 molecule, and this CD5 + B cell subset may be expanded in nonorgan-specific autoimmune diseases. Since autoimmune features are common in lymphoproliferative disorders and the latter be a complication in autoimmune settings, CD5 + B cell may stand at the crossroads of these two conditions. Our hypothesis is, therefore, that there are differences in CD5 + B cells arising during ontogeny ("classical") and those whereby CD5 is induced by various stimuli ("induced"). There is also evidence to support a role for CD5 on B cells, sustaining the proliferation of activated B cells, whereas resting B cells undergo apoptosis.